This article has been updated with comments and additional information from the firm's conference call.

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its fourth-quarter revenues increased 30 percent on strong instrument and reagent growth.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $49.2 million for the three-month period ended Dec. 31, compared to $37.8 million for the fourth quarter of 2008. The company easily beat analysts' consensus estimate of $45.4 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.